<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266524</url>
  </required_header>
  <id_info>
    <org_study_id>527.49</org_study_id>
    <nct_id>NCT02266524</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders</brief_title>
  <official_title>Pharmacokinetics, Safety and Tolerability of Single Oral Doses (0.1, 0.2, 0.4 and 0.8 mg) of Tamsulosin Hydrochloride in Children With Voiding Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate pharmacokinetics, safety, and tolerability of tamsulosin hydrochloride in
      children with voiding disorders
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from dosing to maximum concentration of the analyte in plasma (tmax)</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma (AUC)</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of the AUC0-∞ that is obtained by extrapolation (%AUCtz-∞)</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single-dose administration (AUC0-∞)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal rate constant of the analyte in plasma (λz)</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t1/2)</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time of the analyte in the body after po administration (MRTpo)</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight-normalized Cmax</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight-normalized AUC0-∞</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight-normalized (AUC0-tz)</measure>
    <time_frame>Up to 26 hours after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration after single-dose administration (AUC0-tz)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant changes in physical examination</measure>
    <time_frame>Pre-dose, up to 26 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant changes in vital signs (blood pressure, pulse rate, respiratory rate)</measure>
    <time_frame>Pre-dose, up to 26 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant changes from baseline in orthostatic test</measure>
    <time_frame>Pre-dose and 4 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant changes in 12-lead ECG</measure>
    <time_frame>Pre-dose, up to 26 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically relevant changes from baseline in laboratory tests</measure>
    <time_frame>Pre-dose and 26 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 7 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability by the investigator on a 5-point rating scale</measure>
    <time_frame>26 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Urination Disorders</condition>
  <arm_group>
    <arm_group_label>Tamsulosin hydrochloride, very low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin hydrochloride, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin hydrochloride, medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin hydrochloride, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin hydrochloride, very low dose</intervention_name>
    <arm_group_label>Tamsulosin hydrochloride, very low dose</arm_group_label>
    <other_name>Flomax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin hydrochloride, low dose</intervention_name>
    <arm_group_label>Tamsulosin hydrochloride, low dose</arm_group_label>
    <other_name>Flomax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin hydrochloride, medium dose</intervention_name>
    <arm_group_label>Tamsulosin hydrochloride, medium dose</arm_group_label>
    <other_name>Flomax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin hydrochloride, high dose</intervention_name>
    <arm_group_label>Tamsulosin hydrochloride, high dose</arm_group_label>
    <other_name>Flomax®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Boys and girls with (or a history of) voiding disorders

          -  Age: 5 to 15 years

          -  Body weight and height ≥ 5 % and ≤95 % of normal using nomograms

          -  Signed and dated written informed consent by the parent or guardian and, where
             appropriate, informed assent by the child, prior to admission into the study in
             accordance with good clinical practice (GCP) and the local legislation, has been
             obtained

        Exclusion Criteria:

          -  Clinically significant abnormalities found at, or before randomization at Visit 2
             [i.e., abnormal: vital signs (e.g., hypotension), ECGs, as well as significant
             findings during the physical examination], as determined by the investigator

          -  Clinically relevant conditions including, but not limited to, the following:
             gastrointestinal, cardiovascular (e.g., subjects that fall above the 90th percentile
             according to the blood pressure nomogram in the ISF), hepatic, renal, hematologic,
             metabolic (including diabetes mellitus), immunological, hormonal disorders,
             respiratory disease or cancer

          -  Subjects who had surgery within the last 30 days

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  Subjects that have a neurological impairment or psychiatric disorder that prevents
             their comprehension of consent and their ability to comply with the protocol

          -  History of relevant orthostatic hypotension, fainting spells or blackouts. Postdural
             symptoms occurring (e.g., lightheadedness, dizziness, and fainting) with or without a
             change in blood pressure and / or pulse rate within 6 weeks of Visit 2

          -  Relevant acute infections, especially with regards to urinary tract infections or
             active genitourinary infection

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Subjects with known hypersensitivity to FLOMAX® (tamsulosin hydrochloride) or other
             alpha-blockers

          -  Use of medications classified as cytochrome P450 3A4 (CYP3A4) inhibitors and inducers
             within 10 days prior to administration of trial drug

          -  Intake of drugs with a long half-life (&gt; 24 hours) within less than 10 half-lives of
             the respective drug prior to administration

          -  Participation in another trial with an investigational drug within 1 month prior to
             administration or during the trial

          -  Inability to comply with dietary regimen of study center

          -  Pregnancy or subjects that are breast feeding

          -  All subjects parents and guardians in the investigator's opinion who cannot understand
             the terms of the informed consent form and subject information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Urination Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

